A Case of B-cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma in a Korean Child
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (intermediate DLBCL/BL), is a heterogeneous group with some features resembling DLBCL and others resembling BL. Here, we report a case of intermediate DLBCL/BL in a Korean child. A 2-yr-old male was admitted for evaluation and management of left hip pain. Immunohistochemistry of a biopsy of the femur neck revealed tumor cells positive for CD20, CD10, BCL2, BCL6, and Ki67. A bone marrow (BM) aspirate smear revealed that 49.3% of all nucleated cells were abnormal lymphoid cells, composed of large- and medium-sized cells. Immunophenotyping of the neoplastic cells revealed positivity for CD19, CD10, CD20, and sIg lambda and negativity for CD34, Tdt, and myeloperoxidase (MPO). Cytogenetic and FISH analyses showed a complex karyotype, including t(8;14)(q24.1;q32) and IGH-MYC fusion. Intensive chemotherapy was initiated, including prednisone, vincristine, L-asparaginase, daunorubicin, and central nervous system prophylaxis with intrathecal methotrexate (MTX) and cytarabine. One month after the initial diagnosis, BM examination revealed the persistent of abnormal lymphoid cells; cerebrospinal fluid cytology, including cytospin, showed atypical lymphoid cells. The patient was treated again with cyclophosphamide, vincristine, prednisone, adriamycin, MTX, and intrathecal MTX and cytarabine. The patient died of sepsis 5 months after the second round of chemotherapy.
Abstract
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (intermediate DLBCL/BL), is a heterogeneous group with some features resembling DLBCL and others resembling BL. Here, we report a case of intermediate DLBCL/BL in a Korean child. A 2-yr-old male was admitted for evaluation and management of left hip pain. Immunohistochemistry of a biopsy of the femur neck revealed tumor cells positive for CD20, CD10, BCL2, BCL6, and Ki67. A bone marrow (BM) aspirate smear revealed that 49.3% of all nucleated cells were abnormal lymphoid cells, composed of large- and medium-sized cells. Immunophenotyping of the neoplastic cells revealed positivity for CD19, CD10, CD20, and sIg lambda and negativity for CD34, Tdt, and myeloperoxidase (MPO). Cytogenetic and FISH analyses showed a complex karyotype, including t(8;14)(q24.1;q32) and IGH-MYC fusion. Intensive chemotherapy was initiated, including prednisone, vincristine, L-asparaginase, daunorubicin, and central nervous system prophylaxis with intrathecal methotrexate (MTX) and cytarabine. One month after the initial diagnosis, BM examination revealed the persistent of abnormal lymphoid cells; cerebrospinal fluid cytology, including cytospin, showed atypical lymphoid cells. The patient was treated again with cyclophosphamide, vincristine, prednisone, adriamycin, MTX, and intrathecal MTX and cytarabine. The patient died of sepsis 5 months after the second round of chemotherapy.
참고문헌 (13)
- Hummel M, "A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling", N Engl J Med, 354, pp.2419~2430 (2006)
- Saglio G, "Molecular pathogenesis of diffuse large B-cell lymphoma", Hematologica reports, 2, pp.68~69 (2006)
- Carbone A, "From pathogenesis to pathology", Hum Pathol, 41, pp.621~631 (2010)
- Kluin PM, "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, In WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed", pp.265~266 (2008), IARC Press
- Klapper W, "Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials", Blood, 112, pp.1374~1381 (2008)
- Salaverria I, "The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective", J Clin Oncol, 29, pp.1835~1843 (2011)
- HasserJian RP, "Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma", J Hematop, 2, pp.89~95 (2008)
- Liang X, "Gray zone lymphomas in pediatric patients", Pediatr Dev Pathol, 14, pp.57~63 (2011)
- Patte C, "Results of the randomized international FAB", LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients, 2007, pp.109, 2773~2780
- Quintanilla-Martinez L, "Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux", France. J Hematop, 2, pp.211~236 (2009)
- Le Gouill S, "The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24", c-MYC rearrangement, 2007, pp.92, 1335~1342
- Bellan C, "Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach", Hematol Onco, 27, pp.182~185 (2009)
- Aukema SM, "Double-hit B-cell lymphomas", Blood, 117, pp.2319~2331 (2011)